诺瓦瓦克斯医药(NVAX)股价于2024年11月11日盘中大涨15.94%,引起市场关注。据报道,这一走势与美国食品和药物管理局(FDA)最新决定密切相关。
FDA解除了对诺瓦瓦克斯新冠流感疫苗及独立流感疫苗后期临床试验的限制。此前,由于一些参与者出现不良反应,相关试验曾被FDA叫停进行评估。但经过进一步调查,诺瓦瓦克斯向FDA提交了补充材料,证明那些不良反应与疫苗无关。
FDA的最新决定意味着,诺瓦瓦克斯的疫苗研发项目将重新复苏,进入临床试验最后阶段,为未来商业化推广扫清了障碍。作为一家新冠疫苗领域的后起之秀,诺瓦瓦克斯备受投资者关注。这一利好消息无疑重振了投资者对公司前景的信心,促使股价出现大涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.